In the phase 3 IMMerge trial, risankizumab showed non-inferiority to secukinumab after 16 weeks and superiority in all assessed efficacy endpoints at week 52 in patients with moderate-to-severe plaque psoriasis [1,2].
“Although we have many efficacious drugs in psoriasis now, it is important to know which drug is used when, and of course, which drug is better than others,” said Prof. Richard Warren (University of Manchester, UK). Thus, head-to head studies are important. In this current head-to-head trial, the IL-23 blocker risankizumab was compared with the IL-17 blocker secukinumab in adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy.
Participants (n=327) were randomised to receive either 150 mg risankizumab at weeks 0, 4, and every 12 weeks thereafter or 300 mg secukinumab weekly from week 0 to 4, and every 4 weeks thereafter. Primary outco...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Good response and pruritus reduction in AD with novel selective JAK1 inhibitor Next Article
IL-13 blocker tralokinumab effective in AD »
Table of Contents: AAD 2020
Psoriasis – What Is Hot?
Systemic Therapies for Dermatologists
Hidradenitis Suppurativa/Acne Inversa
Pearls of the Posters
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.